Mutual Advisors LLC grew its stake in shares of Eli Lilly And Co (NYSE:LLY) by 11.3% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,088 shares of the company’s stock after acquiring an additional 620 shares during the period. Mutual Advisors LLC’s holdings in Eli Lilly And Co were worth $471,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in LLY. Chicago Equity Partners LLC grew its position in shares of Eli Lilly And Co by 238.7% during the 4th quarter. Chicago Equity Partners LLC now owns 13,140 shares of the company’s stock valued at $1,110,000 after acquiring an additional 9,260 shares during the period. Engineers Gate Manager LP bought a new position in shares of Eli Lilly And Co during the 4th quarter valued at approximately $1,940,000. Stuart Chaussee & Associates Inc. bought a new position in shares of Eli Lilly And Co during the 4th quarter valued at approximately $595,000. SeaCrest Wealth Management LLC bought a new position in shares of Eli Lilly And Co during the 4th quarter valued at approximately $1,542,000. Finally, Van Cleef Asset Management Inc bought a new position in shares of Eli Lilly And Co during the 4th quarter valued at approximately $435,000. 76.01% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly And Co opened at $86.11 on Tuesday, MarketBeat reports. Eli Lilly And Co has a fifty-two week low of $73.69 and a fifty-two week high of $89.09. The firm has a market cap of $94.30 billion, a PE ratio of 20.12, a P/E/G ratio of 1.47 and a beta of 0.29. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.01 and a current ratio of 1.41.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 24th. The company reported $1.34 EPS for the quarter, topping the Zacks’ consensus estimate of $1.13 by $0.21. Eli Lilly And Co had a return on equity of 35.37% and a net margin of 4.82%. The business had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.51 billion. During the same period in the prior year, the company earned $0.98 EPS. Eli Lilly And Co’s revenue for the quarter was up 9.0% on a year-over-year basis. equities analysts forecast that Eli Lilly And Co will post 5.15 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 10th. Shareholders of record on Wednesday, August 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 2.61%. Eli Lilly And Co’s dividend payout ratio is 52.57%.
A number of research analysts have recently weighed in on LLY shares. Jefferies Financial Group reissued a “buy” rating and set a $91.00 target price on shares of Eli Lilly And Co in a research report on Friday, March 23rd. Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Monday, April 9th. JPMorgan Chase & Co. set a $105.00 price objective on shares of Eli Lilly And Co and gave the stock a “buy” rating in a report on Monday, February 26th. BMO Capital Markets reaffirmed a “sell” rating and issued a $74.00 price objective on shares of Eli Lilly And Co in a report on Wednesday, April 4th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Eli Lilly And Co in a report on Wednesday, April 18th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Eli Lilly And Co currently has an average rating of “Buy” and a consensus target price of $93.89.
In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction on Wednesday, April 25th. The stock was sold at an average price of $80.85, for a total value of $14,553,000.00. Following the transaction, the insider now owns 122,896,904 shares of the company’s stock, valued at approximately $9,936,214,688.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Susan Mahony sold 5,165 shares of the stock in a transaction on Friday, April 13th. The shares were sold at an average price of $80.14, for a total value of $413,923.10. Following the completion of the transaction, the senior vice president now directly owns 45,652 shares in the company, valued at approximately $3,658,551.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 987,464 shares of company stock worth $82,748,955. Company insiders own 0.11% of the company’s stock.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.